Navigation Links
Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
Date:9/9/2010

BASKING RIDGE, N.J., Sept. 9 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel located at 200 Boylston Street in Boston, Massachusetts.  Dr. Mazzo's presentation will be given at 2:40 pm EDT in the Winthrop Room and will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivam
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013   Life Technologies Corporation ... its Applied Biosystems™ 3500 Dx and 3500xL Dx Genetic ... Protection against Health Risks in Mexico ... extension of Life Technologies, capabilities to serve the clinical ... with Sanger -based solutions.  ...
(Date:5/20/2013)... -- TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating ... body,s immune system using patented immunotherapy, announced its common stock ... the ticker symbol "TNIB" commencing May 17, 2013. Investors will ... quotes for TNIB at http://www.otcmarkets.com/stock/TNIB/quote . ... BioTech, Inc. stated, "We are very pleased to provide ...
(Date:5/20/2013)... 20, 2013 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that surveyed U.S. ... greater effect on quality of life is among ... high level of subjectivity and variability of tests ... leaders state that it is difficult to differentiate ...
Breaking Medicine Technology:Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 2TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 3For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2
(Date:5/20/2013)... The automated external defibrillator market ... categories - semi-automated and fully automated defibrillators. Based ... categories, namely, hospitals, pre-hospital, public access, alternate care, ... Automated external defibrillators play an important role in ... Considering the life-saving potential of AEDs, legislations requiring ...
(Date:5/20/2013)... Recent environmental concerns have helped ... and sustainable inputs in packaging products. As such, ... promote the use of sustainable materials, thereby driving ... industry . “Tax subsidies and operating cost savings ... analyst Deonta Smith. “For example, many packaging product ...
(Date:5/20/2013)... In order to prepare for the long hot ... DrSmartphoneMD launched an article series to raise awareness about skincare ... launched with the precautions that need to be taken ... are not one of the 3.5 million cases of skin ... of all skin cancer cases are associated with exposure to ...
(Date:5/20/2013)... Parker Waichman LLP, a national law firm ... defective drugs, has filed a lawsuit on behalf of ... the diabetes drug medication Actos (pioglitazone) caused bladder ... 2013, in the U.S. District Court for the Western ... one of thousands of cases pending in the Actos ...
(Date:5/20/2013)... 20, 2013 Mirena IUD lawsuit ... multidistrict litigation recently established in U.S. District Court, Southern ... According to court records, the litigation’s first Status Conference ... to Plaintiff’s leadership positions were discussed. So far, ... Southern District of New York, all of which allege ...
Breaking Medicine News(10 mins):Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Combat Skin Cancer In Summer Months 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3
... Security Disability Insurance recipients; time-intensive process of receiving benefits can include ... ... Belleville, Ill. (Vocus) June 25, 2008 -- The number ... benefits continued to grow in 2007. This means more people are ...
... of patients admitted to the hospital have alcohol/drug abuse ... sharply in recent years, according to a study in ... Abuse Treatment (JSAT). , "Our results demonstrated ... and the striking financial costs placed on the hospital, ...
... Richer countries perform most, but safety an issue in ... News) -- About 234 million major surgeries are performed ... in high-income countries than in low-income countries, U.S. researchers ... of Public Health, and his colleagues defined major surgeries ...
... TALLAHASSEE, Fla., June 25 Pharmavite, ... has chosen the on-line consumer-centric,program, LearnSomethingAbout(TM), ... Inc. created the engaging, consumer-oriented multimedia,program ... of national retailers., "LearnSomething shares ...
... Mass., June 25 Cynosure, Inc.,(Nasdaq: CYNO ), ... of,light-based aesthetic treatment systems, today announced the opening of ... Located in the Chao,Yang District of Beijing, the office ... sales and marketing for Cynosure China, the company,s,wholly owned ...
... LCA-Vision Inc. (Nasdaq:,LCAV), a leading provider ... brand, is providing an update on the ... for the company,s services., "Macro-economic conditions ... spending, leading to continued softness in,LasikPlus(R) appointments ...
Cached Medicine News:Health News:SSDI Recipients Ask: When Do I Get My Benefits? 2Health News:SSDI Recipients Ask: When Do I Get My Benefits? 3Health News:Study shows high rates, rising costs of alcohol/drug disorders in hospitalized patients 2Health News:Worldwide Surgery Rates Tied to Economic Status 2Health News:Pharmavite Partners With LearnSomething, Inc. on Consumer Education Program, LearnSomethingAbout(TM) 2Health News:Cynosure Expands Presence in China with the Opening of Sales Office in Beijing 2Health News:LCA-Vision Provides Business Update and Market Review 2Health News:LCA-Vision Provides Business Update and Market Review 3Health News:LCA-Vision Provides Business Update and Market Review 4
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , Promega Barrier Tips ...
... Finntip Filters are ideal ... amplification methods, or for ... contamination might occur. They ... DNA/RNA solutions, infectious materials, ...
1000 L, Racked, Filtered, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
Inquire...
Medicine Products: